DNA Methylation Biomarkers Discovery for Aging-Related Diseases
Technology Platforms & Expertise
Online Inquiry

DNA Methylation Biomarkers Discovery for Aging-Related Diseases


Aging-related diseases are diseases whose incidence increases rapidly with age, such as cancer, Alzheimer's disease, atherosclerosis, diabetes, obesity, etc., this means that age is an important risk factor for these diseases. In the context of accelerating population aging around the world, it is crucial that we predict, diagnose, and early control human aging-related diseases through biological techniques.

DNA methylation changes are involved in various processes of aging-related disease development, affecting the function of key genes, and perhaps by using its changes as biomarkers we can identify or monitor pathological processes. However, it is currently known that the DNA methylation clock can be used as an accurate age prediction tool, but its use as a diagnostic biomarker needs to be analyzed on a case-by-case basis.

CD BioSciences offers DNA methylation biomarker discovery services for various diseases. Our services can help researchers advance their research in the early prevention and intervention of aging-related diseases.

Our DNA Methylation Biomarker Discovery Services

CD BioSciences offers a range of services designed to identify and validate potential methylation biomarkers. Our knowledge and technology enable us to assist our clients in measuring and interpreting biomarker changes in disease progression, linking them to therapy development programs.

DNA Methylation Biomarkers Discovery for Aging-Related Diseases

Identifying potential methylation biomarkers

Our comprehensive approach begins with the identification of potential DNA methylation biomarkers associated with aging-related diseases. Leveraging advanced technologies and reliable bioinformatics tools, we conduct genome-wide methylation analysis to pinpoint specific methylation modifications that may serve as valuable indicators of disease progression and susceptibility.

Validating potential methylation biomarkers

Following the initial identification phase, CD BioSciences meticulously validates the generated differential methylation sites or regions as potential biomarkers using targeted approaches. Through rigorous statistical analyses, we seek to confirm the associations between identified biomarkers and aging-related diseases.

Association analysis of validated methylation biomarkers

The validation of DNA methylation biomarkers is further complemented by association analyses, wherein we elucidate the relationships between validated methylation biomarkers and specific aging-related diseases. Our in-depth analysis enables us to decipher the predictive and prognostic value of the identified biomarkers, providing invaluable insights into disease mechanisms and potential therapeutic targets.

Service Options for Aging-Related Disease DNA Methylation Biomarker Discovery

We identify biomarkers of related diseases utilizing DNA methylation analysis assays and provide customized solutions for our clients in different disease areas. Optional services include but are not limited to:

Advantages of Our Services

  • We can analyze methylation pattern specificity for different disease areas and different sample types.
  • We require only minimal sample input for methylation analysis, providing the fastest workflow.
  • We provide easy-to-use automated solutions that fully automate DNA sequence detection and quantification.
  • We offer user-friendly comprehensive reports, including comprehensive analyses of DNA methylation, which can be applied for paper publication.

CD BioSciences has a comprehensive DNA methylation technology platform to support the technical needs of the aging and related disease research process and to provide you with a high level of professional experience and quality service. If you are interested in our services, please feel free to contact us for any of your related needs.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.